A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2010

At a glance

  • Drugs Fexofenadine; Fexofenadine/pseudoephedrine; PF 3654764
  • Indications Allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Aug 2010 Additional trial location [Canada] identified as reported by ClinicalTrials.gov.
    • 03 Aug 2010 Actual initiation date added to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 03 Aug 2010 Actual end date added to 1 May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top